Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Immunology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Histiocytoma Clinical Trials

A listing of Histiocytoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (7) clinical trials

International Rare Histiocytic Disorders Registry (IRHDR)

Histiocytoses are rare diseases caused by an excess of cells called Histiocytes, which can infiltrate the skin, bones, lungs, liver, spleen and the central nervous system. These disorders can range from localized involvement that resolves spontaneously, to progressive disseminated forms that can be debilitating and sometimes life-threatening. The rare histiocytic ...

Phase N/A

Nivolumab (Opdivo ) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma

The primary objective of this study is to investigate the maximum tolerated dose of ABI-009, an mTOR inhibitor, when given sequentially with nivolumab in advanced UPS, LPS, CS, OS and Ewing sarcoma. The secondary objectives are to investigate the disease control rate (DCR) and progression free survival (PFS) using nivolumab/ABI-009 ...

Phase

Ifosfamide and Doxorubicin Radiation Therapy and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma

OBJECTIVES: Primary - Determine survival rates (event-free survival and overall survival [OS]) and the pattern of treatment failure in patients with synovial sarcoma or adult-type soft tissue sarcoma treated with ifosfamide and doxorubicin hydrochloride, radiotherapy, and/or surgery. - Determine the role of ifosfamide and doxorubicin hydrochloride in improving the response ...

Phase

Ipilimumab in Young Patients With Advanced or Refractory Solid Tumors

OBJECTIVES: Primary - To determine the tolerance and toxicity profile of ipilimumab at a range of doses up to, but not exceeding, the highest dose tolerated in patients 21 years of age or younger with advanced or refractory solid tumors. - To assess the pharmacokinetics of ipilimumab in patients with ...

Phase

Bevacizumab and Radiation Therapy for Sarcomas

- The dose of bevacizumab and radiation therapy will be the same for all participants throughout the study. - Bevacizumab will be given as an intravenous infusion every 2 weeks for a total of 4 doses. - Radiation therapy will begin 2 weeks after the first bevacizumab infusion and will ...

Phase

Doxorubicin With Upfront Dexrazoxane Plus Olaratumab for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma

The purpose of this research study is to look at whether giving a drug called dexrazoxane plus olaratumab with standard of care doxorubicin affects the progression of the disease. Dexrazoxane is often given at the same time as doxorubicin to help reduce the incidence and severity of disease of the ...

Phase

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

PRIMARY OBJECTIVES: I. To identify the dose of pazopanib hydrochloride (pazopanib) that is feasible when given in combination with radiation or chemoradiation in pediatric and adult patients newly diagnosed with unresected intermediate- and high-risk non-rhabdomyosarcoma soft tissue sarcomas (NRSTS). II. To compare the rates of near complete pathologic response (> ...

Phase